← Oncology Approval Tracker

FDA DECISION ·

Camcevi

leuprolide mesylate · Foresee Pharmaceuticals

FDA approvalNew formulationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with advanced prostate cancer treated with a six-month subcutaneous leuprolide mesylate depot.

LAMPGEN ANALYSIS

Why it matters

The approval adds a long-interval depot presentation for androgen deprivation.

What research teams should watch

Verify the formulation and injection date and align subsequent administrations with testosterone follow-up.

PRIMARY RECORDS

Sources